Difference between revisions of "Lung cancer after neoadjuvant therapy"

From Libre Pathology
Jump to navigation Jump to search
(create)
 
Line 7: Line 7:
{{Reflist|1}}
{{Reflist|1}}


[[Category:Lung pathology]]
[[Category:Pulmonary pathology]]

Revision as of 19:35, 21 February 2024

Creating Lung cancer after neoadjuvant therapy is assessed using a consensus protocol.[1]

See also

References

  1. ↑ Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y (May 2020). "IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy". J Thorac Oncol 15 (5): 709–740. doi:10.1016/j.jtho.2020.01.005. PMC 8173999. PMID 32004713. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173999/.
Retrieved from "https://librepathology.org/w/index.php?title=Lung_cancer_after_neoadjuvant_therapy&oldid=52653"